Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233868 | 0.90 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL11961332 | 0.88 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL12619300 | 0.88 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL23421684 | 0.87 | TLR8 (0.61) | TLR8TLR7 | |
| SCHEMBL12619280 | 0.87 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL1095204 | 0.87 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL1802552 | 0.86 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL10325903 | 0.86 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL1802559 | 0.85 | TLR8 (0.71) | TLR8TLR7 | |
| SCHEMBL1104740 | 0.85 | TLR8 (0.74) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940797-B1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC (US) | 2012-08-01 | — | — | EP | claimed |
| US-20180303845-A1 | USE OF TLR8 AGONISTS TO TREAT CANCER | VENTIRX PHARMACEUTICALS, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10016440-B2 | Methods of enhancing antibody-dependent cellular cytotoxicity | VENTIRX PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2560658-B1 | ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | VENTIRX PHARMACEUTICALS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170027954-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | VENTIRX PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-3081558-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Array Biopharma, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20130236449-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8304407-B2 | 8-substituted benzoazepines as toll-like receptor modulators | ARRAY BIOPHARMA INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304407-B2 | 8-substituted benzoazepines as toll-like receptor modulators | ARRAY BIOPHARMA INC. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1940797-B1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153622-B2 | modulating a patient's immune system; treating autoimmunity, inflammation allergy, asthma, transplant rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency; (1E,4E)-ethyl 2-amino-8-(perfluoroethyl)-3H-benzo[b]azepine-4-carboxylate; antiinflammatory, anticarcinogenic agents | ARRAY BIOPHARMA INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153622-B2 | modulating a patient's immune system; treating autoimmunity, inflammation allergy, asthma, transplant rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency; (1E,4E)-ethyl 2-amino-8-(perfluoroethyl)-3H-benzo[b]azepine-4-carboxylate; antiinflammatory, anticarcinogenic agents | ARRAY BIOPHARMA INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120003213-A1 | Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity | VENTIRX PHARMACEUTICALS, INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2322510-A2 | 8-substituted benzoazepines as toll-like receptor modulators | Array Biopharma, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR7, TLR9 | TLR8 1/4885TLR7 2/4885 |
| US-20120003213-A1 | Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity | GZMB, CD47, FCGR3B | TLR8 1934/4885TLR7 2308/4885 |
| US-20180303845-A1 | USE OF TLR8 AGONISTS TO TREAT CANCER | TLR8, TLR1, TLR3 | TLR8 1/4885TLR7 5/4885 |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR7, TLR9 | TLR8 1/4885TLR7 2/4885 |
| US-20130236449-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | GZMB, CD47, FCGR3B | TLR8 1934/4885TLR7 2308/4885 |
| US-20170027954-A1 | METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | GZMB, CD47, FCGR3B | TLR8 1934/4885TLR7 2308/4885 |
| US-10016440-B2 | Methods of enhancing antibody-dependent cellular cytotoxicity | GZMB, CD47, FCGR3B | TLR8 1934/4885TLR7 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.